PPIE — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL23512388	1.00	1/20
SCHEMBL25146703	0.96	1/20
SCHEMBL23512300	0.96	1/20
SCHEMBL23512635	0.95	1/20
SCHEMBL25146723	0.95	1/20
SCHEMBL25146936	0.95	1/20
SCHEMBL23512529	0.94	1/20
SCHEMBL23512639	0.94	1/20
SCHEMBL25146434	0.94	1/20
SCHEMBL26955733	0.94	1/20
SCHEMBL23512638	0.94	1/20
SCHEMBL25146492	0.93	1/20
SCHEMBL25146508	0.93	1/20
SCHEMBL25146696	0.93	1/20
SCHEMBL25146783	0.93	1/20
SCHEMBL23512301	0.93	1/20
SCHEMBL23512390	0.93	1/20
SCHEMBL23512400	0.92	1/20
SCHEMBL23512637	0.92	1/20
SCHEMBL23512306	0.92	1/20

Clinical trials — most relevant to PPIE by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia	PHASE3	COMPLETED
Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Cancer Cancer.	PHASE1/PHASE2	COMPLETED
NEO100 and High-Grade Meningioma	PHASE2	RECRUITING
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
SNX-5422 to Treat Solid Tumor Cancers and Lymphomas	PHASE1	COMPLETED
Effectiveness of Physiologic Testing in PPI Non-Responders	EARLY_PHASE1	COMPLETED
A Study on Psychopathological Progress of Early Schizophrenia-Like Disorder (SOPRES)	nan	UNKNOWN
Identification of Acute Intermittent Porphyria Modifying Genes	nan	RECRUITING
Biomarkers in the Diagnosis and Prognosis of NAFLD	nan	RECRUITING
Role of Circulating Pyrophosphate as a Biomarker of Mediacalcinosis in Type 2 Diabetic Patients	nan	RECRUITING
Portable Measurement of Protoporphyrin IX in the Skin	nan	COMPLETED
Genotype-supported Versus Conventional Proton Pump Inhibitor Dosing	nan	COMPLETED
Biomarkers in Idiopathic Juvenile Arthritis	nan	UNKNOWN
Major Depression and Messenger RNAs	nan	COMPLETED
Risk Factors of Porphyria Cutanea Tarda (PCT)	nan	COMPLETED
Cerebellar Mutism Syndrome Study	nan	RECRUITING
Cohort of Patients With Rare Iron Overloads Excluding C282Y Homozygosity	nan	COMPLETED
A Patient-tailored Genetic/Biomarker/iPSC Combined Approach in ALS - PERMEALS	nan	RECRUITING
Establishment of Human Cellular Disease Models for Wilson Disease	nan	COMPLETED
Clinical Grade MIS Device for Cervical Assessment to Predict Preterm Birth	nan	COMPLETED
Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))	nan	COMPLETED
Treatment Response of Maintenance Dose of Proton Pump Inhibitor in Patients With Nonerosive Gatroesophageal Reflux Disease	nan	COMPLETED
Role of Amino Acids and Genetic Disorder in Pathogenesis of Heart Failure	nan	UNKNOWN
Quantification of GADD34 Expression in RA	nan	COMPLETED
A Study of the Genetic Analysis of Brain Disorders	nan	COMPLETED
Prospective Arm of Conduct - Edwards SAPIEN3 PPI Registry	nan	COMPLETED
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED
Pulmonary Hypertension, Hypoxia and Sickle Cell Disease	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PPIE binder may also engage these)

Protein	Name	Similarity
Q9QZH3	—	1.000	Q9QZH3 →
Q5R723	—	1.000	Q5R723 →
A4FV72	—	1.000	A4FV72 →
P0C1I2	—	0.997	P0C1I2 →
Q9V3G3	—	0.994	Q9V3G3 →
Q26548	—	0.989	Q26548 →
Q4G338	—	0.989	Q4G338 →
Q5B4E7	—	0.986	Q5B4E7 →
Q5U8Z7	—	0.985	Q5U8Z7 →
Q8SRE1	—	0.985	Q8SRE1 →
Q9CR16	—	0.984	Q9CR16 →
Q9C566	—	0.984	Q9C566 →
Q6CBP4	—	0.984	Q6CBP4 →
P0CP79	—	0.983	P0CP79 →
Q2U0E0	—	0.983	Q2U0E0 →
P0C1I0	—	0.983	P0C1I0 →
Q8X166	—	0.982	Q8X166 →
PPID	Peptidyl-prolyl cis-trans isomerase D	0.982	landscape →
Q5B4R3	—	0.982	Q5B4R3 →
B3A0R0	—	0.982	B3A0R0 →
P52018	—	0.982	P52018 →
Q4I5R9	—	0.982	Q4I5R9 →
P23285	—	0.981	P23285 →
P0CP83	—	0.981	P0CP83 →
P0CP82	—	0.981	P0CP82 →
Q0P5D0	—	0.981	Q0P5D0 →
Q6CL78	—	0.981	Q6CL78 →
P24368	—	0.981	P24368 →
Q7S7Z6	—	0.981	Q7S7Z6 →
P52009	—	0.981	P52009 →